AstraZeneca - Health Xplore

AstraZeneca’s Etcamah Receives Accelerated FDA Approval for Breast Cancer

FDA Grants Accelerated Approval to AstraZeneca’s Breast Cancer Drug Etcamah

The accelerated approval was based on results from AstraZeneca’s pivotal SERENA-6 Phase III trial, which showed Etcamah in combination with a CDK4/6 inhibitor reduced the risk of disease progression or death by 56% in advanced HR-positive breast cancer patients with an emergent ESR1 tumour mutation.

imphoenix82
September 7, 2026
0 Comments
299 Views

AstraZeneca Completes $1.5B Zegfrovy License Deal with Dizal Pharmaceutical

News

AstraZeneca, Dizal Complete $1.5B Deal for Lung Cancer Drug Zegfrovy

Under the agreement, AstraZeneca has acquired worldwide rights to develop and commercialise Zegfrovy.

imphoenix82
September 2, 2026
0 Comments
255 Views

US FDA Approves Lupin's Sodium Zirconium Cyclosilicate for Oral Suspension

News

Lupin’s Sodium Zirconium Cyclosilicate for Oral Suspension Approved in the US

US FDA has approved Lupin’s Sodium Zirconium Cyclosilicate for Oral Suspension as a bioequivalent to AstraZeneca’s Lokelma for the treatment of high levels of potassium in the blood, or hyperkalemia, in adults.

imphoenix82
August 11, 2026
0 Comments
130 Views

CDSCO Approves Expanded Indication for AstraZeneca's Enhertu in Breast Cancer

News

AstraZeneca’s Enhertu Gains CDSCO Approval for Additional Breast Cancer Indication

With this approval, AstraZeneca can market Enhertu in India for the neoadjuvant treatment of adults with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, where trastuzumab deruxtecan is followed by a taxane, trastuzumab and pertuzumab (THP).

imphoenix82
July 28, 2026
0 Comments
48 Views

AstraZeneca Receives CHMP Positive Opinions for Trixeo and Enhertu

News

CHMP Recommends AstraZeneca’s Trixeo for Asthma, Enhertu for Breast Cancer

The Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s Trixeo for the maintenance treatment of asthma and Enhertu, in combination with pertuzumab, for the first-line treatment of adults with unresectable or metastatic HER2-positive breast cancer in the European Union (EU).

imphoenix82
July 25, 2026
0 Comments
162 Views

Response Research to Emerging Infectious Diseases Inform

Skin Type Before Choosing Skin Care Products

Using Lemon on Your Face & Ways to

Most Common Exercise Machines at the Gym

Contact Info

Tag: AstraZeneca

FDA Grants Accelerated Approval to AstraZeneca’s Breast Cancer Drug Etcamah

AstraZeneca, Dizal Complete $1.5B Deal for Lung Cancer Drug Zegfrovy

Lupin’s Sodium Zirconium Cyclosilicate for Oral Suspension Approved in the US

AstraZeneca’s Enhertu Gains CDSCO Approval for Additional Breast Cancer Indication

CHMP Recommends AstraZeneca’s Trixeo for Asthma, Enhertu for Breast Cancer

Lilly Acquires AtaiBeckley to Advance Therapies for Treatment-Resistant Depression

Nadda Inaugurates 10 Critical Care Blocks, 12 Public.

IHW Council Roundtable Calls for National Patient Charter

iPHEX 2026 Concludes with USD 5 Billion in.

About Us

Quick Link

Top Categories

Top Posts

Laser Treatments for Anti-aging: Types, Benefits,

Lilly’s Retatrutide Shows Powerful Weight Loss

National Registry for Implantable Medical Devices: